Anavex Life Sciences Corp (AVXL)

[georgejjl]

Anavex is planning a pivotal trial of ANAVEX®2-73 (blarcamesine) in Parkinson’s disease dementia after submitting the results of the study to the FDA to obtain regulatory guidance.

So the CTAD was really focused on the Dementia portion of the study, the Dementia portion of the PDD study. What is now -- will come up, and we will present that in a proper fashion, either at a conference or in a peer-reviewed form or in a webinar or that fashion, we will provide the entire data of all the other measures of the CDR system, which are many more than the ones presented at CTAD, which also was a very short time frame of presentation of only 10 minutes, so we have to factor that in. And it will also include the actigraphy data and other data related to Parkinson's disease. So this will be something which we are also planning to present on a relatively short notice. And so in order to have that full picture of PDD, and the same applies here, this data, this aggregated data will be put in front of the FDA and to seek guidance in order to design a pivotal study in PDD.

https://seekingalpha.com/article/4405917-anavex-life-sciences-corp-avxl-ceo-christopher-missling-on-q1-2021-results-earnings-call?part=single

Good luck and GOD bless,